Companies
Companies
FDA extends Exelixis zanzalintinib review by three months to March 3, 2027
Updated safety and efficacy data prompted more review time for the zanzalintinib–atezolizumab application in metastatic colorectal cancer. The extension does not decide whether the regimen will be approved.
Claire Morgan · TickerGrove Healthcare Desk · Published · Exelixis, Inc. Form 8-K — PDUFA extension
Sources
Verified facts from Exelixis, Inc. Form 8-K AccNo 0000939767-26-000108, Item 8.01 Other Events. Period of Report / earliest event September 10, 2026; accepted September 11, 2026; CIK 0000939767; trading symbol EXEL (Nasdaq). FDA notified Exelixis on September 10, 2026 that it extended the review period for the NDA for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months after treating updated safety and efficacy data (submitted in response to an FDA information request) as a major amendment. Updated PDUFA action date: March 3, 2027. This is a review-timeline extension only — not an approval, not a Complete Response Letter, and not a withdrawal. No trial statistics, prior PDUFA dates beyond the new March 3, 2027 date, partnership economics, or share-price direction are stated here.
Facts are as of the September 10, 2026 FDA notification disclosed in the September 11, 2026 Form 8-K. This article covers a review-timeline extension only — not an approval, CRL, or withdrawal.
On September 10, 2026, the FDA notified Exelixis, Inc. (NASDAQ: EXEL) that it had extended by three months its review of the new drug application for zanzalintinib in combination with atezolizumab for patients with metastatic colorectal cancer. The agency treated updated safety and efficacy data, submitted in response to an FDA information request, as a major amendment.
The new Prescription Drug User Fee Act (PDUFA) action date is March 3, 2027. That moves the review timeline; it does not establish whether the FDA will approve or reject the application. Exelixis disclosed the extension in a Form 8-K filed September 11.
Verified Figures
- **March 3, 2027:** New PDUFA action date. - **Three months:** Length of the review-period extension. - **September 10, 2026:** Date the FDA notified Exelixis.
Source: Exelixis Form 8-K, Item 8.01, accession 0000939767-26-000108.
What the FDA changed
The extension followed Exelixis’ submission of updated safety and efficacy data in response to the agency’s request for information. By deeming those data a major amendment, the FDA added time to review the application. In plain English, the new data mean more review time.
The application covers zanzalintinib together with atezolizumab for metastatic colorectal cancer. March 3, 2027 is now the stated action date for that review.
What this does not decide
The disclosed action is a review-timeline extension. It is not an approval, a Complete Response Letter or a withdrawal. The additional review time does not, by itself, establish the FDA’s judgment on the application’s safety and efficacy data or its eventual decision.
Exelixis reported the notification under Item 8.01, Other Events, of its September 11 filing, with September 10 as the earliest event date.
Prior PDUFA date, trial statistics, and partnership economics remain outside this disclosure
This package does not invent a prior PDUFA date beyond March 3, 2027, ORR/OS/PFS or other trial figures, Roche/Genentech partnership economics for atezolizumab, peak-sales estimates, or share-price direction.
Document trail
Sources & evidence
Primary documents used for this piece.
Exelixis, Inc. via SEC EDGAR
Exelixis Form 8-K — zanzalintinib NDA PDUFA extension (AccNo 0000939767-26-000108)
SEC Form 8-K · 2026-09-11
U.S. Securities and Exchange Commission (EDGAR)
Exelixis Form 8-K filing index — AccNo 0000939767-26-000108
SEC Form 8-K index · 2026-09-11
Corrections
We do not silently rewrite a published line. Material corrections receive a visible correction note, and we preserve the article’s update history.
Discuss this story. Join the TickerGrove community to talk companies, earnings, and markets, or request future coverage.